Intellikine Inc.
This article was originally published in Start Up
Executive Summary
Intellikine is developing a group of compounds capable of selectively inhibiting different PI3K isoforms. It can mix and match components to achieve a variety of therapeutic goals. The company's lead program, an mTOR inhibitor for cancer, is nearing the clinic. The start-up also sees significant potential for its PI3 kinase inhibitors in inflammatory diseases and hopes to begin a Phase I trial in that area next year.
You may also be interested in...
Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.
Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.
Paloma Pharmaceuticals Inc.
Paloma Pharmaceuticals Inc. is initially opting for an ophthalmology indication for its PI3K program. It plans to bring its lead compound, an allosteric inhibitor, into clinical trials for age-related macular degeneration in 2010. If all goes well, Paloma might move the same compound into a Phase I oncology trial later that year.